Grufity logoGrufity logo
StocksFundsSearch FilingsAPI

Ibio Inc Stock Research

IBIO

0.33USD-0.00(0.00%)Market Closedas of 21 Sep 2023, 09:31 am
Watchlist

Market Summary

USD0.33-0.00
Market Closedas of 21 Sep 2023, 09:31 am
0.00%

IBIO Stock Price

IBIO RSI Chart

IBIO Valuation

Market Cap

4.1M

Price/Earnings (Trailing)

-0.05

Price/Sales (Trailing)

3.21

Price/Free Cashflow

-0.09

IBIO Price/Sales (Trailing)

IBIO Profitability

Return on Equity

-437.23%

Return on Assets

-171.29%

Free Cashflow Yield

-1.1K%

IBIO Fundamentals

IBIO Revenue

IBIO Earnings

Earnings (TTM)

-76.0M

Earnings Y/Y

41.13%

Earnings Q/Q

78.26%

Price Action

52 Week Range

0.269.25
(Low)(High)

Last 7 days

-16.4%

Last 30 days

-12.3%

Last 90 days

-49.0%

Trailing 12 Months

-96.1%

IBIO Financial Health

Current Ratio

1.22

IBIO Investor Care

Shares Dilution (1Y)

41.85%

Diluted EPS (TTM)

-7.98

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales

Latest Insider Trading transactions for IBIO

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2023-08-28
Brenner Martin
sold
-1,528
0.3051
-5,011
see remarks
2023-07-27
Brenner Martin
sold
-2,307
0.511091
-4,515
see remarks
2023-07-12
Brenner Martin
sold
-27,520
0.5853
-47,020
see remarks
2023-06-26
Brenner Martin
acquired
-
-
75,833
see remarks
2023-06-22
Brenner Martin
back to issuer
-
-
-75,833
see remarks
2023-06-21
Brenner Martin
sold
-2,848
0.680898
-4,184
see remarks
2023-05-22
Brenner Martin
sold
-3,910
0.935057
-4,182
see remarks
2023-04-24
Brenner Martin
sold
-5,257
1.1998
-4,382
see remarks
2023-03-31
Duran Felipe
acquired
-
-
37,500
chief financial officer
2023-03-31
Brenner Martin
acquired
-
-
50,000
see remarks

1–10 of 36

Which funds bought or sold IBIO recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2023-08-21
OSAIC HOLDINGS, INC.
added
4.95
-698
308
-%
2023-08-15
HARBOUR INVESTMENTS, INC.
unchanged
-
-1,176
488
-%
2023-08-15
WELLS FARGO & COMPANY/MN
added
13.00
-139
69.00
-%
2023-08-15
Retirement Group, LLC
new
-
174
174
-%
2023-08-15
Belpointe Asset Management LLC
sold off
-100
-1,706
-
-%
2023-08-14
CITADEL ADVISORS LLC
added
165
-3,488
12,208
-%
2023-08-14
Royal Bank of Canada
reduced
-74.14
-5,000
-
-%
2023-08-14
VANGUARD GROUP INC
reduced
-1.35
-767,590
312,493
-%
2023-08-14
BRIDGEWAY CAPITAL MANAGEMENT, LLC
sold off
-100
-52,000
-
-%
2023-08-14
NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO
new
-
49.00
49.00
-%

1–10 of 38

Latest Funds Activity

Are funds buying IBIO calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own IBIO
No. of Funds

Schedule 13G FIlings of Ibio

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 09, 2023
vanguard group inc
5.28%
475,593
SC 13G
Jul 08, 2022
blackrock inc.
1.8%
3,960,718
SC 13G
Feb 03, 2022
blackrock inc.
7.1%
15,476,683
SC 13G/A
Feb 02, 2021
blackrock inc.
5.5%
11,575,051
SC 13G
Aug 13, 2020
eastern capital ltd
0.6%
1e+06
SC 13D/A
Aug 11, 2020
eastern capital ltd
5.8%
8,629,693
SC 13D/A
Aug 07, 2020
eastern capital ltd
22.3%
33,114,597
SC 13D/A
Aug 06, 2020
eastern capital ltd
22.3%
33,114,597
SC 13D/A
Mar 31, 2020
eastern capital ltd
28.7%
37,382,734
SC 13D/A
Mar 05, 2020
eastern capital ltd
35.6%
37,382,734
SC 13D/A

Recent SEC filings of Ibio

View All Filings
Date Filed Form Type Document
Aug 30, 2023
4
Insider Trading
Aug 24, 2023
4
Insider Trading
Aug 24, 2023
4
Insider Trading
Aug 15, 2023
D
D
Aug 14, 2023
424B3
Prospectus Filed
Aug 11, 2023
EFFECT
EFFECT
Aug 10, 2023
CORRESP
CORRESP
Aug 09, 2023
UPLOAD
UPLOAD
Aug 07, 2023
8-K
Current Report
Aug 07, 2023
424B5
Prospectus Filed

Peers (Alternatives to Ibio)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
145.2B
26.6B
4.13% 21.09%
18.2
5.46
0.75% 21.34%
94.5B
27.4B
-0.16% 19.51%
17.24
3.45
-0.48% 32.56%
39.4B
10.7B
-6.80% -20.18%
32.68
3.7
-53.67% -91.41%
37.7B
10.0B
-1.71% 27.59%
14.15
3.78
-6.23% 29.40%
MID-CAP
11.2B
1.7B
5.59% 6.81%
63.29
6.67
29.01% 1345.90%
4.5B
-
-3.04% 140.92%
-7.66
48.33
54.84% -12.96%
3.1B
-
-4.51% -22.98%
-23.78
37.44
122.90% 54.78%
2.0B
80.2M
6.46% -52.82%
-6.01
24.54
42.17% -39.82%
SMALL-CAP
1.5B
121.2M
4.38% -25.42%
-5.13
12.17
-70.36% -531.73%
980.2M
15.3M
-15.63% 3.04%
-5.4
64.02
1090.59% -36.57%
664.9M
1.6B
-12.64% -74.33%
-1.13
0.42
23.74% 60.24%
221.7M
-
-17.58% -90.72%
-1.05
1.62
116.83% 16.61%
146.7M
-
-8.84% -84.12%
-0.74
0.61
113.96% -15.19%
112.7M
2.1M
-6.14% -67.90%
-1.12
54.83
487.70% -8.66%
4.1M
-
-12.28% -96.10%
-0.05
3.21
- -129.46%

Ibio News

Benzinga
Plant Based Biologics Market Current Trends, Future Aspect Analysis 2023-2031.
Benzinga,
10 hours ago
MarketWatch
Jazzwise magazine
MarketWatch
MarketWatch

Returns for IBIO

Cumulative Returns on IBIO

-44.8%


10-Year Cumulative Returns

-57.7%


7-Year Cumulative Returns

-56.9%


5-Year Cumulative Returns

-82.5%


3-Year Cumulative Returns

Risks for IBIO

What is the probability of a big loss on IBIO?

100%


Probability that Ibio stock will be more than 20% underwater in next one year

100%


Probability that Ibio stock will be more than 30% underwater in next one year.

93.8%


Probability that Ibio stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does IBIO drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Ibio was unfortunately bought at previous high price.

Drawdowns

Financials for Ibio

Income Statement (Last 12 Months)
(In Thousands)
Income Statement (Last 12 Months)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q12022Q42022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q32018Q22018Q12017Q4
Revenue---2,3832,5431,5082,0452,3713,0002,3311,9401,6381,3131,7442,0812,0181,314865367444500459
Gross Profit---2,1672,4258021,2419091,8901,6281,51293540.00---------
Operating Expenses-4.2%55,10757,52651,85730,87129,75830,56632,02026,49123,09018,52014,93816,35416,57717,77417,80616,99516,26915,18314,67114,64015,042
  S&GA Expenses-4.8%35,67237,46334,12821,50921,50621,79922,03119,51017,17614,09211,36511,77011,63512,44712,33212,10311,86411,05810,68510,58410,816
  R&D Expenses-3.1%19,43520,06317,7299,3628,2528,7679,9896,9815,9144,4283,5734,5844,9425,3275,4744,8924,4054,1253,9864,0564,226
Interest Expenses4.5%8057701,4121,2231,8352,4502,4542,4562,4602,4602,4662,3252,1832,0441,9001,9041,9081,9111,9151,9191,922
Net Income6.3%-76,030-81,126-50,303-33,134-28,405-24,616-23,207-26,864-23,879-19,512-16,439-17,407-16,954-17,660-17,593-17,510-17,249-16,679-16,105-8,364-8,315
Net Income Margin----21.11*-3.25*-2.78*-2.41*-2.28*-8.95*-10.24*-10.06*-10.04*-13.26*-9.72*-8.49*-8.72*------
Free Cashflow6.0%-45,631-48,548-44,810-39,617-41,371-37,965-34,984-29,918-25,431-19,625-14,423-14,285-14,693-16,130-------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q32018Q22018Q1
Assets-14.3%44.0052.0085.0099.0011512614414714314511794.0042.0036.0035.0031.0036.0040.0043.0043.0031.00
  Current Assets-29.1%27.0038.0064.0045.0060.0067.0090.0010510711185.0062.0010.004.002.005.0010.0014.0016.0016.004.00
    Cash Equivalents77.5%7.004.0010.0023.0040.0045.0063.0077.0085.0091.0078.0055.0010.004.002.004.009.0013.008.004.003.00
  Inventory----4.003.002.001.000.00-------------
  Net PPE2.7%4.004.003.001.0035.0033.0010.009.006.005.004.004.003.003.003.0024.0025.0025.0025.0025.0025.00
Liabilities-18.1%27.0033.0036.0036.0036.0036.0043.0038.0038.0038.0037.0038.0038.0037.0037.0028.0029.0029.0030.0027.0027.00
  Current Liabilities-19.8%22.0028.0032.0030.008.008.008.007.006.006.005.005.006.005.005.003.004.004.005.002.002.00
Shareholder's Equity-7.6%17.0019.0048.0063.0079.0091.0010110910510780.0057.004.00--2.007.0011.0013.0016.004.00
  Retained Earnings-2.6%-282-275-242-223-206-194-182-173-173-166-157-150-146-135-110-105-101-97.09-92.63-88.23-83.81
  Additional Paid-In Capital1.9%30029529128828628528328227827323820715113510810810810810610488.00
Shares Outstanding0%12.0012.009.009.009.009.009.009.009.008.006.006.004.002.001.001.001.001.001.001.000.00
Minority Interest--------0.02-0.02-0.01-0.01-0.01-0.01-0.01-0.01-0.01-0.010.000.000.000.000.00
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Last 12 Months)
(In Thousands)
Description(%) Q/Q2023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q32018Q22018Q1
Cashflow From Operations5.3%-36,969-39,041-42,092-37,480-33,203-34,608-32,341-30,064-26,705-23,142-18,128-13,345-13,870-14,219-15,484-13,975-12,958-12,323-11,241-13,480-13,870
  Share Based Compensation6.7%5,1244,8024,7784,3773,7942,8942,0561,5861,210899671388227213236241375509638770874
Cashflow From Investing3329.3%7,492-23251.00-5,127-8,512-13,043-25,027-26,478-24,390-20,472-7,724-1,154-507-550-731-990-1,099-1,445-1,257-1,079-1,322
Cashflow From Financing76.7%-449-1,923-4,896-6,125-3,2031,54542,64678,835125,682131,231101,29365,19215,3835,0462,3103,45319,69519,82022,59322,4066,170

IBIO Income Statement

2022-12-31
Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended6 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2022
Dec. 31, 2021
Condensed Consolidated Statements of Operations and Comprehensive Loss    
Revenues$ 0$ 0 $ 84
Operating expenses:    
Research and development2,7791,859$ 5,3272,993
General and administrative7,7945,37212,8829,547
Total operating expenses10,5737,23118,20912,540
Operating loss(10,573)(7,231)(18,209)(12,456)
Other income (expense):    
Interest expense(31)0(31) 
Interest income413514071
Royalty income05 5
Total other income (expense)104010976
Consolidated net loss from continuing operations(10,563)(7,191)(18,100)(12,380)
Net loss attributable to noncontrolling interest00 1
Net loss attributable to iBio, Inc. from continuing operations(10,563)(7,191)(18,100)(12,379)
Preferred stock dividends - iBio CDMO Tracking Stock0(22)0(88)
Net loss available to iBio, Inc. stockholders from continuing operations(10,563)(7,213)(18,100)(12,467)
Loss from discontinued operations(22,990)(4,729)(33,583)(8,480)
Net loss available to iBio, Inc. stockholders(33,553)(11,942)(51,683)(20,947)
Comprehensive loss:    
Consolidated net loss(33,553)(11,920)(51,683)(20,860)
Other comprehensive loss - unrealized gain ( loss) on debt securities56(27)46(28)
Comprehensive loss$ (33,497)$ (11,947)$ (51,637)$ (20,888)
Loss per common share attributable to iBio, Inc. stockholders - basic - continuing operations$ (1.08)$ (0.83)$ (1.94)$ (1.43)
Loss per common share attributable to iBio, Inc. stockholders - diluted - continuing operations(1.08)(0.83)(1.94)(1.43)
Loss per common share attributable to iBio, Inc. stockholders - basic - discontinued operations(2.34)(0.54)(3.60)(0.97)
Loss per common share attributable to iBio, Inc. stockholders - diluted - discontinued operations(2.34)(0.54)(3.60)(0.97)
Loss per common share attributable to iBio, Inc. stockholders - basic - total(3.42)(1.37)(5.54)(2.40)
Loss per common share attributable to iBio, Inc. stockholders - diluted - total$ (3.42)$ (1.37)$ (5.54)$ (2.40)
Weighted-average common shares outstanding - basic9,8078,7159,3248,715
Weighted-average common shares outstanding - diluted9,8078,7159,3248,715

IBIO Balance Sheet

2022-12-31
Condensed Consolidated Balance Sheets - USD ($)
Dec. 31, 2022
Jun. 30, 2022
Current assets:  
Cash and cash equivalents$ 3,696,000$ 22,676,000
Investments in debt securities5,929,00010,845,000
Accounts receivable - trade970,0001,000,000
Settlement receivable - current portion5,100,0005,100,000
Convertible promissory note receivable and accrued interest1,669,000 
Prepaid expenses and other current assets414,0001,549,000
Current assets held for sale20,457,0003,900,000
Total Current Assets38,235,00045,070,000
Restricted cash253,0005,996,000
Convertible promissory note receivable and accrued interest 1,631,000
Finance lease right-of-use assets, net of accumulated amortization746,000 
Operating lease right-of-use asset2,873,0003,068,000
Fixed assets, net of accumulated depreciation4,245,0001,373,000
Intangible assets, net of accumulated amortization5,398,0004,851,000
Security deposits50,00029,000
Prepaid expenses - noncurrent 74,000
Noncurrent assets held for sale 37,314,000
Total Assets51,800,00099,406,000
Current liabilities:  
Accounts payable4,002,0004,264,000
Accrued expenses5,001,0003,764,000
Finance lease obligations - current portion259,000 
Operating lease obligation - current portion315,00091,000
Equipment financing payable - current portion152,000 
Term note payable - net of deferred financing costs16,011,00022,161,000
Contract liabilities88,000100,000
Current liabilities related to assets held for sale1,947,00056,000
Total Current Liabilities27,775,00030,436,000
Finance lease obligations - net of current portion490,000 
Operating lease obligation - net of current portion3,324,0003,514,000
Equipment financing payable - net of current portion323,000 
Accrued expenses - noncurrent1,065,000 
Noncurrent liabilities related to assets held for sale 1,971,000
Total Liabilities32,977,00035,921,000
iBio, Inc. Stockholders' Equity:  
Series 2022 Convertible Preferred Stock - $0.001 par value; 1,000,000 shares authorized; 0 and 1,000 shares issued and outstanding as of December 31, 2022 and June 30, 2022, respectively
Common stock - $0.001 par value; 275,000,000 shares authorized at December 31, 2022 and June 30, 2022; 12,368,287 and 8,727,158 shares issued and outstanding as of December 31, 2022 and June 30, 2022, respectively12,0009,000
Additional paid-in capital294,591,000287,619,000
Accumulated other comprehensive loss(167,000)(213,000)
Accumulated deficit(275,613,000)(223,930,000)
Total iBio, Inc. Stockholders' Equity18,823,00063,485,000
Total Liabilities and Equity$ 51,800,000$ 99,406,000
Thomas F. Isett
80
iBio, Inc., a biotechnology company, provides contract development and manufacturing services to collaborators and third-party customers in the United States. The company operates in two segments: Biopharmaceuticals and Bioprocessing. Its lead therapeutic candidate is IBIO-100 that is being advanced for investigational new drug development for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis. The company is also developing vaccine candidates comprising IBIO-200 and IBIO-201, which are in preclinical development for the prevention of severe acute respiratory syndrome coronavirus 2; and IBIO-400 for the treatment of classical swine fever. In addition, it is developing recombinant proteins for third parties on a catalog and custom basis; and offers a range of process development, manufacturing, filling and finishing, and bio analytic services. iBio, Inc. has a license agreement with Planet Biotechnology, Inc. to develop therapeutics for infectious diseases; collaboration agreement with The Texas A&M University System for the development of coronavirus disease 2019 vaccine candidates; license agreement with the University of Natural Resources and Life Sciences, Vienna; and collaboration agreement with CC-Pharming Ltd. The company is headquartered in Bryan, Texas.